A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use
CNS Drugs · 2026-08 · 40 (8) · 1165-1177
DOI: 10.1007/s40263-026-01302-y ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CNS Drugs, online erschienen am 15.06.2026. Verfasst von Avia Merenlender Wagner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel. Avia.MerenlenderWa…. Hauptthemen laut MEDLINE: Risperidone, Antipsychotic Agents, Schizophrenia, Psychotic Disorders. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research and Development, Teva Pharmaceutical Industries, Ltd..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel. Avia.MerenlenderWagner@teva.co.il.
- Magic Wand Research LLC, Philadelphia, PA, USA.
- Teva PLIVA Croatia Ltd, Research and Development, Zagreb, Croatia.
- Nuventra Pharma Sciences, Pharmacokinetics and Clinical Pharmacology, Carrboro, NC, USA.
- Teva Branded Pharmaceutical Products LLC, West Chester, PA, USA.
- Teva Pharmaceutical Industries Ltd., Quantitative Pharmacology and Biosimilar Sciences, 12 Hatrufa Street, 42504, Netanya, Israel.
Förderung
- Research and Development, Teva Pharmaceutical Industries, Ltd.
Zitieren
APA
Merenlender Wagner, A., Perlstein, I., Farkas, P., Lamson, M., Loupe, P., Spiegelstein, O., Kalmanczhelyi, A., Tiver, R., Franzenburg, K. R., Harary, E., & Elgart, A. (2026). A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. CNS Drugs, 40(8), 1165-1177. https://doi.org/10.1007/s40263-026-01302-y
Vancouver
Merenlender Wagner A, Perlstein I, Farkas P, Lamson M, Loupe P, Spiegelstein O, et al. A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. CNS Drugs. 2026;40(8):1165-1177. doi:10.1007/s40263-026-01302-y
BibTeX
@article{MerenlenderWagner2026,
author = {Merenlender Wagner, Avia and Perlstein, Itay and Farkas, Pavel and Lamson, Michael and Loupe, Pippa and Spiegelstein, Ofer and Kalmanczhelyi, Attila and Tiver, Ryan and Franzenburg, Kelli R and Harary, Eran and Elgart, Anna},
title = {A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use},
journal = {CNS Drugs},
year = {2026},
volume = {40},
number = {8},
pages = {1165--1177},
doi = {10.1007/s40263-026-01302-y}
}
EUVIMED